Study on the Impact of 18F-Fluciclovine PET/CT on Predicting Outcomes of 177Lu-PSMA-617 Therapy in Prostate Cancer Patients

Sponsor: VA Greater Los Angeles Healthcare System

Sponsor score: 0
Inactive

ClinicalTrials ID:NCT06706921

Provider View

This study is exploring how a specific type of imaging scan, called 18F-Fluciclovine PET/CT, can help predict the effectiveness of a treatment for prostate cancer that has spread and is resistant to standard hormone therapy. The study is open to veterans only.

Patient Parameters

Program Overview

This research is being conducted at a single center and involves patients with advanced prostate cancer that no longer responds to hormone therapy. These patients are scheduled to receive a treatment called LuPSMA RLT. As part of the study, they will undergo several imaging scans, including a special PET/CT scan using 18F-Fluciclovine, both before and after their treatment cycles. The goal is to see if these scans can help predict how well the treatment is working.

Description

In this study, patients will have a series of PET/CT scans to measure how much of the imaging agent is taken up by cancer lesions in their body. These scans will be done before and after the LuPSMA RLT treatment cycles. The scans will help researchers compare the uptake of different imaging agents and see how it changes over time. The results from these scans will be used to assess the effectiveness of the treatment and will be compared to the patients' clinical outcomes. All follow-up care and assessments will be conducted at the study center.

Eligibility Criteria

Inclusion Criteria

  • Have advanced prostate cancer that is resistant to hormone therapy and are scheduled for LuPSMA RLT.
  • Willing to undergo multiple PET/CT scans before and after treatment.
  • Able to provide written consent to participate in the study.

Exclusion Criteria

  • Under 18 years old at the time of the study.
  • Have a medical condition or serious illness that could interfere with the study.
  • Have any contraindications to receiving LuPSMA RLT.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.